A/Prof Sayed Ali is an experienced medical oncologist at Icon Cancer Centre Midland, also consulting at St John of God Midland Hospital and Midwest Cancer Centre in Geraldton. He completed his Bachelor of Medicine, Bachelor of Surgery (MBBS) degree at Utkal University, India before completing postgraduate training at the St Vincent physician training network in Sydney. A/Prof Ali subsequently undertook specialist medical oncology training at the Royal Prince Alfred Hospital and Liverpool Hospital before becoming a fellow of the Royal Australasian College of Physicians (FRACP). He commenced his elective year as a clinical trial fellow at Sydney’s Westmead Hospital, coordinating several early clinical trials of novel targeted therapies and immunotherapies in different tumor types.
A/Prof Ali maintains a strong interest in teaching and research, particularly in the field of cancer immunology and immunotherapy. He was instrumental in establishing services for melanoma and immunotherapy at The Canberra Hospital and is also an Adjunct Associate Professor at University of Canberra and Clinical Senior Lecturer at Curtin University, Western Australia. A/Prof Ali is currently undertaking translational research in conjunction with the Australian National University (ANU) Medical School and the University of Canberra to identify patients who benefit from immune checkpoint inhibitors and predict toxicity. He is a member of Kirkbride Melanoma Advisory Service and of several leading cancer trial groups including American Society of Clinical Oncology (ASCO), Medical Oncology Group of Australia (MOGA), Clinical Oncology Society of Australia (COSA) and the Australia and New Zealand Melanoma Trials Group (ANZMTG).
Throughout his professional career, A/Prof Ali has contributed to multiple research articles and has presented at national and international conferences. His research has been published in several high impact journals, including the Asia-Pacific Journal of Clinical Oncology, Journal of Clinical Oncology and Melanoma Research, focusing on immune oncology, predictive biomarkers of immune checkpoint inhibitors. His clinical experience covers a broad range of solid tumour malignancies with special interest in immunotherapy, gastrointestinal cancer, colorectal cancer, lung cancer, melanoma and prostate cancer.